Prices Could Be Slashed Under U.K.’s New Drug-Pricing Scheme
This article was originally published in The Pink Sheet Daily
Executive Summary
Prices may decrease, but at least wider societal benefits are to be included in NICE’s assessment in the U.K.’s new value-based pricing (VBP) scheme for new pharmaceuticals, a change long demanded by critics of the health technology assessment body.
You may also be interested in...
Pharma Hopes EU Commission Policy Report Will Lead To Real Dialogue
The European Commission's latest policy document dedicated to making the pharma industry a better global competitor advocates a new, co-operative approach, but lacks detail. The industry, though, believes the document offers hope for constructive debate in key areas.
Pharma Hopes EU Commission Policy Report Will Lead To Real Dialogue
The European Commission's latest policy document dedicated to making the pharma industry a better global competitor advocates a new, co-operative approach, but lacks detail. The industry, though, believes the document offers hope for constructive debate in key areas.
Pharma Hopes EU Commission Policy Report Will Lead To Real Dialogue
The European Commission's latest policy document dedicated to making the pharma industry a better global competitor advocates a new, co-operative approach – but it lacks detail.